Skip to content

Study · In vitro (cells) · 2023

4 results

Thymosin α1 interacts with Galectin-1 modulating the β-galactosides affinity and inducing alteration in the biological activity.

Matteucci C, Nepravishta R, Argaw-Denboba A, Mandaliti W, Giovinazzo A, Petrone V, Balestrieri E, Sinibaldi-Vallebona P, Pica F, Paci M, Garaci E

International immunopharmacology5 Apr 2023Cited by 4 (Europe PMC)

PMID37028279 (opens in a new tab)DOI10.1016/j.intimp.2023.110113 (opens in a new tab)PepBankPUB-37028279
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In vitro, thymosin alpha‑1 specifically inhibited the hemagglutination activity of Galectin-1.

    In plain wordsIn lab tests, thymosin alpha‑1 blocked a clumping activity of Galectin-1.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseGal-1 hemagglutination activity
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tα1 specifically inhibited the hemagglutination activity of Gal-1, the Gal-1 dependent in vitro formation of endothelial cell tubular structures, and the migration of cancer cells in wound healing assay.
  2. 02LabIn vitro (cells)Activity measurement

    In vitro, thymosin alpha‑1 inhibited Galectin-1-dependent formation of endothelial cell tubular structures.

    In plain wordsIn cells in a dish, thymosin alpha‑1 blocked blood-vessel-like tubes forming in a Galectin-1 dependent way.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseGal-1 dependent endothelial cell tubular structure formation
    Study

    n: not reported in source

    Endothelial cells
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tα1 specifically inhibited the hemagglutination activity of Gal-1, the Gal-1 dependent in vitro formation of endothelial cell tubular structures, and the migration of cancer cells in wound healing assay.
  3. 03LabIn vitro (cells)Activity measurement

    In a wound healing assay, thymosin alpha‑1 inhibited the migration of cancer cells.

    In plain wordsIn cells in a dish, thymosin alpha‑1 slowed the movement of cancer cells.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseCancer cell migration in wound healing assay
    Study

    n: not reported in source

    Cancer cells, wound healing assay
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tα1 specifically inhibited the hemagglutination activity of Gal-1, the Gal-1 dependent in vitro formation of endothelial cell tubular structures, and the migration of cancer cells in wound healing assay.
  4. 04LabIn vitro (cell-free)Mechanism

    In molecular and cellular assays, thymosin alpha‑1 interacted with Galectin-1.

    In plain wordsIn lab tests, thymosin alpha‑1 was shown to bind a protein called Galectin-1.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableInteraction of Tα1 with Galectin-1
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Using molecular and cellular methodological approaches, we demonstrated the interaction between these two proteins.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.